BMJ Group Jun 21 2025 In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.  For more than a decade, ticagrelor (Brilinta in the US and Brilique in Europe) has been recommended for patients with acute coronary syndrome - a range of conditions related to sudden reduced blood flow to the heart. Last December, an investigation by The BMJ found serious data integrity problems in